Healthcare Innovations • Sunday 26 July 2020
Innovative healthcare & alternative remedies • 9
New non-drug osteoporosis option
T e fi ght against osteoporosis has stepped up a gear with the introduction of Marodyne LiV - the world’s fi rst clinically-approved, non-invasive, non-drug option for osteoporosis prevention
Set to change the way consumers and medics deal with the bone-thin- ning disease, Marodyne LiV works by delivering a precise and targeted low-magnitude mechanical signal at a frequency of exactly 30 Hz per second to the person standing on the device. T ese low acceleration, high frequency vibrations send signals to stimulate your Mesenchymal Stem Cells. T ink of these cells as a “bone building factory” as they are primarily responsible
for
building and ma in ta in in g bones throughout the body.
When you step
onto the low plat- form, it automati- cally adjusts to your weight and mass. A faint buzzing sensa- tion is felt as you stand on
Reader Offer:
buy before 31.08.2020 and have the standard
5-year warranty extended for free to a 7-year by quoting ‘FREE7’ when ordering.
the device and
it only takes 10 minutes each day to see results.
Certifi ed and safe Marodyne LiV can be safely used alongside all prescription drugs currently available to treat osteopo- rosis. Certifi ed as a safe and eff ective
tool, it is supported by a number of clinical studies that show LiV can assist in the prevention of osteopo- rosis in post-menopausal women and promote bone and muscle growth in women suff ering from osteopenia or at risk of developing osteoporosis.
“It felt like a miracle worker… my bones are no longer considered osteoporotic.” Jane Ryan, 68
‘Miracle worker’ Award-winning author and play- wright Jane Ryan, 68, was diagnosed with osteoporosis aged 60 after snap- ping her femur ‘like a matchstick’. She was prescribed medication to help halt the disease but, like many other people, didn’t feel well on it. Jane was relieved to fi nd a non-invasive, non-drug intervention in Marodyne LiV. She has been doing 10 minutes of low intensity vibration training on the device each day for the past two and a half years and the impact has been outstanding. “It felt like a miracle worker to me. When I received my latest dexa scans, the results clearly showed my bones were no longer considered osteoporotic.”
Great potential “T e Royal Osteoporosis Society is encouraged to see the results so far from the Marodyne LiV clinical studies and its potential as a safe and eff ective tool for the preven- tion of osteoporosis,” says Henry Mace, Head of Clinical Partnerships, Royal Osteoporosis Society. “We look forward to working with Marodyne LiV and are watching with great interest to understand the diff er- ence it makes to people living with the condition.”
Osteoporosis – the scale of the problem • 3 million people in the UK are estimated to have osteoporosis
• It is estimated that 500,000 women aged 50-64 have osteoporosis: of these 46,000 will break a bone within a year
• More than 500,000 broken bones are caused by osteoporosis each year – that’s 1,400 per day and one every minute
• 54% of people who fractured a bone have experienced height loss or a change in their body shape
• 1 in 2 women and 1 in 5 men are expected to break a bone each year • 1 in 4 people dies within a year of suffering a hip fracture
Marodyne LiV costs £2995 including a travel case and 5-year warranty. For advice and a no-obligation discussion, call 0117 253 0400.
marodyne.co.uk
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
